Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases

C. Katz, Steven; A. Burga, Rachel; McCormack, Elise; Wang, Lijuan; Mooring, Wesley; R. Point, Gary; D. Khare, Pranay; Thorn, Mitchell; Ma, Qiangzhong; F. Stainken, Brian; O. Assanah, Earle; Davies, Robin; Joseph Espat, N.; P. Junghans, Richard

doi:10.1158/1078-0432.ccr-14-1421

Public

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases

Published in Clinical Cancer Research • Apr 8, 2015

Authors:

Steven C. Katz

Rachel A. Burga

Elise McCormack

Abstract

PURPOSE: Chimeric antigen receptor-modified T cells (CAR-T) have demonstrated encouraging results in early-phase clinical trials. Successful adaptation of CAR-T technology for CEA-expressing adenocarcinoma liver metastases, a major cause of death in patients with gastrointestinal cancers, has yet to...

Subject

Medicine

Chimeric antigen receptor

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!